Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBRUTINIB vs IMBRUVICA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Terminal elimination half-life is approximately 4–6 hours. No clinically relevant accumulation is observed at steady state.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism by CYP2D6. The active metabolite is PCI-45227.
Ibrutinib is primarily metabolized by cytochrome P450 (CYP) 3A4, and to a minor extent by CYP2D6. The major active metabolite is PCI-45227, which has similar inhibitory activity against BTK. Avoid coadministration with strong or moderate CYP3A4 inhibitors or inducers.
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Primarily via feces (approximately 80% as metabolites and parent drug); renal excretion accounts for <10% of the dose.
97.3% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 97.3% bound to plasma proteins (primarily albumin).
Apparent Vd is approximately 10,000 L (large), indicating extensive tissue distribution.
Volume of distribution is approximately 10,000 L (extremely large, indicating extensive tissue distribution, but not typically expressed in L/kg).
Oral bioavailability is 62% (range 52-74%) under fasted conditions; food increases AUC by 1.7-fold.
Oral bioavailability is approximately 2.9% (low due to extensive first-pass metabolism and poor absorption; food increases exposure by about 60%).
No dose adjustment required for creatinine clearance ≥25 m L/min. Insufficient data for patients with Cr Cl <25 m L/min or on dialysis.
No dose adjustment required for GFR ≥ 30 m L/min. For GFR < 30 m L/min, use with caution and monitor closely; no specific dose recommendation available.
Child-Pugh class A: No adjustment. Child-Pugh class B: Reduce dose to 280 mg once daily. Child-Pugh class C: Reduce dose to 140 mg once daily.
Child-Pugh A: 280 mg orally once daily (starting dose for CLL/SLL, WM, MZL, c GVHD) or 420 mg orally once daily (starting dose for MCL). Child-Pugh B: 140 mg orally once daily (CLL/SLL, WM, MZL, c GVHD) or 280 mg orally once daily (MCL). Child-Pugh C: Not recommended.
Adolescents (≥12 years): 420 mg once daily; weight-based dosing not established. For pediatric patients <12 years: not approved.
Not approved for pediatric use. Safety and efficacy not established.
No specific dose adjustment; monitor for cardiac adverse events (atrial fibrillation, hypertension) and bleeding risk due to higher incidence in elderly.
No specific dose adjustment required; patients ≥65 years experienced higher incidence of certain adverse events (e.g., atrial fibrillation, hypertension) in clinical trials; monitor closely.
Hemorrhage: Fatal bleeding events have occurred in patients receiving ibrutinib. Major hemorrhage (e.g., gastrointestinal, intracranial) has been reported. Monitor for signs of bleeding. Consider benefit-risk of holding ibrutinib for 3-7 days pre- and post-surgery depending on procedure.
Hemorrhage: Fatal and serious hemorrhagic events have occurred in patients treated with IMBRUVICA. Major hemorrhage (≥ Grade 3) has occurred in up to 6% of patients. Bleeding events include intracranial hemorrhage, gastrointestinal bleeding, hematuria, and post-procedural hemorrhage. Monitor for signs of bleeding. Consider benefit-risk of surgery and the need for temporary interruption.
Hemorrhage: Increased risk of bleeding, especially in patients on anticoagulants or antiplatelet agents. Avoid concomitant use of warfarin.,Infections: Fatal and serious infections (including bacterial, viral, fungal) have occurred. Consider prophylaxis in patients at increased risk.,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia have occurred. Monitor blood counts monthly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor cardiac function, especially in patients with cardiac risk factors.,Hypertension: New-onset or worsening hypertension has been reported. Monitor blood pressure and manage appropriately.,Second primary malignancies: Other malignancies (including skin cancers) have occurred. Perform skin cancer monitoring.,Tumor lysis syndrome: Risk is increased in patients with high tumor burden. Monitor and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have been observed. Monitor hepatic function.
Hemorrhage: risk of bleeding, including fatal events; consider withholding for at least 3-7 days pre- and post-surgery,Infections: fatal and serious infections have occurred (e.g., pneumonia, sepsis); monitor for infections,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts,Cardiac arrhythmias: atrial fibrillation and ventricular tachyarrhythmias; monitor electrocardiogram and manage as appropriate,Tumor lysis syndrome: risk in patients with high tumor burden; ensure adequate hydration and monitoring,Hypertension: monitor blood pressure and initiate antihypertensive therapy as needed,Second primary malignancies: including skin cancers and other carcinomas,Hepatotoxicity: elevations in liver enzymes; monitor hepatic function,Embryo-fetal toxicity: can cause fetal harm; advise women of reproductive potential to avoid pregnancy
Concomitant use with warfarin or other vitamin K antagonists (increased bleeding risk) is not recommended but not absolutely contraindicated; use with caution.,Severe hepatic impairment (Child-Pugh class C) – use not recommended.
None
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they can increase drug levels and toxicity. Take with a full glass of water; may be taken with or without food but avoid high-fat meals as they may increase absorption variability.
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos. These fruits inhibit CYP3A4 and increase ibrutinib levels, raising toxicity risk (bleeding, arrhythmias). No other significant food interactions.
Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotoxic at exposures below the human AUC at the clinical dose. There are no adequate and well-controlled studies in pregnant women. Use during first trimester may cause structural abnormalities; second and third trimester use may impair fetal B-cell development and hematopoiesis.
Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy unless benefit outweighs risk. For first trimester: high risk due to critical organogenesis; second and third trimesters: may cause fetal harm, including low birth weight and developmental abnormalities.
No data on presence in human milk, effects on breastfed infant, or milk production. Ibrutinib and its active metabolite are detected in rat milk at concentrations higher than maternal plasma. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 1 week after last dose. M/P ratio unknown.
No specific dosing adjustments for pregnancy have been established due to lack of human pharmacokinetic data. Pregnancy may alter drug clearance via increased hepatic metabolism and renal function; however, no dose adjustment recommendations can be made. Use only if maternal benefit outweighs fetal risk, with consideration of therapeutic drug monitoring if available.
No specific dose adjustments established. Consider alternative therapy if pregnancy occurs. Systemic exposure may decrease due to increased plasma volume and hepatic metabolism, but no PK data in pregnancy. Do not adjust dose; discontinue if pregnancy occurs unless benefit justifies risk.
Monitor for atrial fibrillation (occurrence ~6-16%, higher risk in elderly). Obtain baseline ECG and monitor for bleeding due to antiplatelet effect (avoid concurrent anticoagulants unless necessary). Check for tumor lysis syndrome risk, especially in high tumor burden. Ibrutinib is a strong CYP3A4 inhibitor; avoid co-administration with sensitive CYP3A4 substrates or adjust doses. Monitor for hypertension and myelosuppression.
Monitor for atrial fibrillation (ECG if palpitations), bleeding risk due to antiplatelet effect (hold 3-7 days before surgery), and tumor lysis syndrome (especially CLL with high lymphocytosis). CYP3A4 substrate: avoid strong inhibitors (ketoconazole, clarithromycin) and reduce dose with moderate inhibitors (fluconazole, diltiazem). Check for HBV reactivation before starting.
Take exactly as prescribed; do not miss doses or stop without consulting your doctor.,Take capsules whole with water at the same time each day; do not open or chew.,Avoid grapefruit, Seville oranges, and starfruit during treatment.,Report any unusual bleeding, bruising, or black/tarry stools immediately.,Contact your healthcare provider if you experience irregular heartbeat, chest pain, or dizziness.,Use effective contraception during treatment and for 1 month after last dose.,Do not take with strong CYP3A4 inhibitors unless directed; avoid St. John's wort.
Take with a full glass of water at the same time each day. Swallow capsules whole, do not open, break, or chew.,Do not drink grapefruit juice, Seville oranges, or pomelos while taking this medication.,Report any new or worsening bruising, bleeding, black/tarry stools, or pink/dark urine immediately.,Seek medical attention for symptoms of atrial fibrillation like palpitations, chest discomfort, or shortness of breath.,Avoid activities that increase bleeding risk (e.g., contact sports) until you know how the drug affects you.,Inform all healthcare providers (including dentists) that you are taking ibrutinib before any procedures.
"Ibrutinib, a potent Bruton's tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. Saquinavir, a protease inhibitor and potent CYP3A4 inhibitor, may significantly increase the plasma concentration of ibrutinib by reducing its clearance. This elevation in ibrutinib exposure can potentiate its adverse effects, including myelosuppression, atrial fibrillation, hemorrhage, and infections, necessitating dose adjustment or alternative therapy."
"Ibrutinib, a Bruton's tyrosine kinase inhibitor, can inhibit organic anion transporters (OATs), leading to decreased renal clearance of sulfamethoxazole. This results in increased plasma concentrations of sulfamethoxazole, potentially enhancing its therapeutic effects and risk of dose-dependent toxicities such as hypersensitivity reactions, hematologic abnormalities, and crystalluria. Patients may experience prolonged QT interval or decreased renal function due to sulfamethoxazole accumulation."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBRUTINIB vs IMBRUVICA, answered by our medical review team.
IBRUTINIB is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.. IMBRUVICA is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBRUTINIB and IMBRUVICA depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBRUTINIB is: Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.. The standard adult dose of IMBRUVICA is: 560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBRUTINIB and IMBRUVICA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBRUTINIB is classified as Category D/X. Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotox. IMBRUVICA is classified as Category C. Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.